One-Year Outcomes in Anticoagulated Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the Greek Antiplatelet Atrial Fibrillation Registry

*2nd Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece;

†Red Cross General Hospital, Athens, Greece;

‡Department of Cardiology, Patras University Hospital, Patras, Greece;

§Cardiology Department, Konstantopoulio General Hospital, Athens, Greece;

¶Sismanoglion General Hospital, Athens, Greece;

║General Hospital “G. Papanikolaou”, Thessaloniki, Greece;

**Ioannina University Hospital, Ioannina, Greece;

††Department of Cardiology “Asklepeion” General Hospital Voula, Attica, Greece;

‡‡Department of Cardiology, Heraklion University Hospital, Crete, Greece;

§§Tzanion Hospital, Piraeus, Greece;

¶¶Elpis General Hospital, Athens, Greece;

║║KAT General Hospital, Athens, Greece;

***Thriasio General Hospital, Elefsina, Greece;

†††Cardiology Department and Cardiac Cathetherization Lab, University Hospital of Alexandroupolis, Alexandroupolis, Greece;

‡‡‡1st Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;

§§§Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece;

¶¶¶Alexandra General Hospital, Athens, Greece; and

║║║First Cardiology Clinic, Medical School, Hippokration Hospital Athens, National and Kapodistrian University of Athens, Athens Greece.

Correspondence: Dimitrios Alexopoulos, MD, FACC, FESC, National and Kapodistrian University of Athens Medical School, Attikon University Hospital, Rimini 1, Chaidari, 12462 Athens, Greece (e-mail: [email protected]).

GRAPE-AF study has received funding by the Hellenic Cardiological Society.

D. Alexopoulos has received lecturing honoraria/advisory board fees from Astrazeneca, Bayer, Boehringer Ingelheim, Pfizer, Medtronic, Biotronik, and Chiesi Hellas. I. Zarifis has received lecturing honoraria from Boehringer Ingelheim. L. Poulimenos has received research grants and honoraria from Astra Zeneca, Bayer, Boehringer-Ingelheim, ELPEN, Menarini, MSD, Novartis, Pfizer, Servier outside the submitted work. E. Skalidis has received lecturing honoraria/advisory board fees from Astrazeneca, Bayer, Boehringer Ingelheim, Medtronic. V. Voudris has received lecturing honoraria/advisory board fees from Bayer and Medtronic. Other authors report no relationships that could be construed as a conflict of interest.

ClinicalTrials.gov Identifier: NCT03362788 (December 5, 2017).

留言 (0)

沒有登入
gif